CAI

Caris Life Sciences, Inc. is a biotechnology company operating in the healthcare sector with a significant market presence. The company's market capitalization stands at $7.45B, indicating its substantial scale. With revenue of $649.06M (TTM) and 1,769 employees, Caris Life Sciences has established itself as a notable player in the industry. The company's financial health is characterized by negative profitability metrics, with an operating margin of 15.1% and a profit margin of -28.8%. The gross margin stands at 60.2%, indicating that a significant portion of revenue is retained after accounting for production costs. However, the net income (TTM) is -$681,859,968, suggesting ongoing losses. The company's balance sheet is notable for its substantial cash reserves of $755.49M and debt of $426.74M, resulting in a debt-to-equity ratio of 89.21. The valuation context surrounding Caris Life Sciences is marked by a forward P/E ratio of 144.07, which may be considered elevated given the company's profitability challenges. The revenue growth rate (YoY) stands at 113.4%, indicating rapid expansion in recent periods. However, the absence of dividend payments and payout ratio data suggests that Caris Life Sciences may prioritize reinvestment or other uses for its earnings rather than distributing them to shareholders.